SEC Form 3 · accession 0001140361-15-026005
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
EcoR1 Capital, LLC
10% Owner
Period of report
Jun 26, 2015
Accepted (ET)
Jun 30, 2015 · 1:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 2,843,170 | I | See Note |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and Mr. Nodelman. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.